pSivida Corp. (PSDV)

2.22
0.06 2.42
NASDAQ : Health Technology
Prev Close 2.27
Open 2.26
Day Low/High 2.13 / 2.27
52 Wk Low/High 0.93 / 2.88
Volume 300.85K
Avg Volume 358.80K
Exchange NASDAQ
Shares Outstanding 45.16M
Market Cap 51.94M
EPS -0.50
P/E Ratio N/A
Div & Yield N.A. (N.A)
PSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces Second Quarter Fiscal Year 2018 Financial Results Release Date And Conference Call Information

Conference Call Scheduled for 4:30 p.m. ET on Wednesday, February 7th

PSivida Submits New Drug Application (NDA) For Durasert™ Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA

PSivida Submits New Drug Application (NDA) For Durasert™ Three-Year Treatment For Posterior Segment Uveitis To The U.S. FDA

Proven Durasert Technology Has to Date Received FDA Approval for Three of the Four Sustained Release Drug Products Approved for Back-of-the-Eye Diseases

HSS And PSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data

HSS And PSivida Report Positive Phase 1 Knee Osteoarthritis Pain Study Data

Sustained Release Technology Well Tolerated and Provides Pain Reduction

PSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date And Conference Call Information

PSivida Corp. Announces First Quarter Fiscal Year 2018 Financial Results Release Date And Conference Call Information

Conference Call Scheduled for 8:30 a.m. ET on Tuesday, November 7th

PSivida And Nicox Enter Strategic Collaboration Agreement To Develop Sustained Release Drug To Lower Intraocular Pressure In Patients With Glaucoma

PSivida And Nicox Enter Strategic Collaboration Agreement To Develop Sustained Release Drug To Lower Intraocular Pressure In Patients With Glaucoma

Focus will be on Combining pSivida's Bioerodible Sustained Release Delivery Technology with Nicox's New Nitric Oxide Donating Compounds

First Week of January 2018 Options Trading For pSivida (PSDV)

Investors in pSivida Corp saw new options begin trading this week, for the January 2018 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 238 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.